These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21985170)

  • 21. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tight binding of cytochrome b
    Kim D; Kim V; McCarty KD; Guengerich FP
    J Biol Chem; 2021; 296():100571. PubMed ID: 33753170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor.
    Lu Y; Wang E; Chen Y; Zhou B; Zhao J; Xiang L; Qian Y; Jiang J; Zhao L; Xiong X; Lu Z; Wu D; Liu B; Yan J; Zhang R; Zhang H; Hu C; Li X
    J Clin Invest; 2020 Jul; 130(7):3791-3804. PubMed ID: 32510471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.
    Jafari A; Dadkhahfar S; Perseh S
    Crit Rev Oncol Hematol; 2020 Jul; 151():102982. PubMed ID: 32460133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents.
    Tucci M; Roca E; Ferrari L; Pia A; Dalla Volta A; Bedussi F; Buttigliero C; Vittorio Scagliotti G; Sigala S; Berruti A
    Endocrine; 2019 Jun; 64(3):724-726. PubMed ID: 31065911
    [No Abstract]   [Full Text] [Related]  

  • 26. Systemic treatment for metastatic prostate cancer.
    Gravis G
    Asian J Urol; 2019 Apr; 6(2):162-168. PubMed ID: 31061802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.
    Guengerich FP; Yoshimoto FK
    Chem Rev; 2018 Jul; 118(14):6573-6655. PubMed ID: 29932643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.
    El-Amm J; Nassabein R; Aragon-Ching JB
    Cancer Manag Res; 2017; 9():299-306. PubMed ID: 28744160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.
    Guengerich FP
    Chem Res Toxicol; 2017 Jan; 30(1):2-12. PubMed ID: 27472660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment.
    Vagia E; Economopoulou P; Oikonomopoulos N; Athanasiadis I; Dimitriadis G; Psyrri A
    Front Oncol; 2015; 5():10. PubMed ID: 25699235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Droperidol for treatment of nausea and vomiting in palliative care patients.
    Storrar J; Hitchens M; Platt T; Dorman S
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD006938. PubMed ID: 25429434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer.
    Zobniw CM; Causebrook A; Fong MK
    Res Rep Urol; 2014; 6():97-105. PubMed ID: 25157341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
    Sanford M
    Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Castration-resistant prostate cancer: potential targets and therapies.
    Parray A; Siddique HR; Nanda S; Konety BR; Saleem M
    Biologics; 2012; 6():267-76. PubMed ID: 22956858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abiraterone acetate: in metastatic castration-resistant prostate cancer.
    Yang LP
    Drugs; 2011 Oct; 71(15):2067-77. PubMed ID: 21985170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
    Scott LJ; Yang LPH; Lyseng-Williamson KA
    Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.
    Hoy SM
    Drugs; 2013 Dec; 73(18):2077-91. PubMed ID: 24271422
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.